Binding mode selection determines the action of ecstasy homologs at monoamine transporters

Molecular Pharmacology

Volumn 89, Issue 1, 2016, Pages 165-175

  Sandtner, Walter ^a   Stockner, Thomas ^a   Hasenhuetl, Peter S ^a   Partilla, John S ^c   Seddik, Amir ^e   Zhang, Yuan Wei ^f   Cao, Jianjing ^d   Holy, Marion ^a   Steinkellner, Thomas ^a   Rudnick, Gary ^f   Baumann, Michael H ^c   Ecker, Gerhard F ^d   Newman, Amy Hauck ^d   Sitte, Harald H ^a,b  

^a Institute of Pharmacology   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Designer Drug Research Unit   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e UNIVERSITY OF VIENNA   (Austria)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXY N METHYLAMPHETAMINE; 3,4 METHYLENEDIOXY N,N DIMETHYLAMPHETAMINE; 3,4 METHYLENEDIOXY N,N,N TRIMETHYLAMPHETAMINE; 3,4 METHYLENEDIOXYAMPHETAMINE DERIVATIVE; DOPAMINE TRANSPORTER; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; MIDOMAFETAMINE; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN ELECTROPHYSIOLOGY; BRAIN SYNAPTOSOME; BRAIN TISSUE; COMPETITIVE INHIBITION; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DISSOCIATION RATE CONSTANT; DRUG PROTEIN BINDING; EMBRYO; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; HYDROPHOBICITY; MALE; MOLECULAR DOCKING; NONHUMAN; PKA; PRIORITY JOURNAL; PROTEIN CONFORMATION; RAT; SYNAPTOSOME; ANIMAL; CHEMISTRY; HEK293 CELL LINE; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; SPRAGUE DAWLEY RAT; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BINDING SITES; BIOLOGICAL TRANSPORT; HEK293 CELLS; HELA CELLS; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, SPRAGUE-DAWLEY; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84958225273     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.101394     Document Type: Article

References (53)

1. Barker EL, Moore KR, Rakhshan F, and Blakely RD (1999) Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J Neurosci 19:4705-4717.
2. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, and Sitte HH et al. (2013) Powerful cocaine-like actions of 3, 4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology 38:552-562.
3. Baumann MH, Wang X, and Rothman RB (2007) 3, 4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: A reappraisal of past and present findings. Psychopharmacology (Berl) 189:407-424.
4. Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, Raniszewska K, Newman AH, Javitch JA, Weinstein H, and Gether U et al. (2008) The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 11: 780-789.
5. Blough BE, Landavazo A, Partilla JS, Baumann MH, Decker AM, Page KM, and Rothman RB (2014) Hybrid dopamine uptake blocker-serotonin releaser ligands: A new twist on transporter-focused therapeutics. ACS Med Chem Lett 5: 623-627.
6. Boehm S (1999) ATP stimulates sympathetic transmitter release via presynaptic P2X purinoceptors. J Neurosci 19:737-746.
7. Celik L, Sinning S, Severinsen K, Hansen CG, Møller MS, Bols M, Wiborg O, and Schiøtt B (2008) Binding of serotonin to the human serotonin transporter. Molecular modeling and experimental validation. J Am Chem Soc 130:3853-3865.
8. Chen JG, Liu-Chen S, and Rudnick G (1997) External cysteine residues in the serotonin transporter. Biochemistry 36:1479-1486.
9. Feige JN, Sage D, Wahli W, Desvergne B, and Gelman L (2005) PixFRET, an ImageJ plug-in for FRET calculation that can accommodate variations in spectral bleedthroughs. Microsc Res Tech 68:51-58.
10. Fenollar-Ferrer C, Stockner T, Schwarz TC, Pal A, Gotovina J, Hofmaier T, Jayaraman K, Adhikary S, Kudlacek O, and Mehdipour AR et al. (2014) Structure and regulatory interactions of the cytoplasmic terminal domains of serotonin transporter. Biochemistry 53:5444-5460.
11. Forrest LR, Zhang YW, Jacobs MT, Gesmonde J, Xie L, Honig BH, and Rudnick G (2008) Mechanism for alternating access in neurotransmitter transporters. Proc Natl Acad Sci USA 105:10338-10343
12. Gasteiger J and Marsili M (1980) Iterative partial equalization of orbital electronegativity-A rapid access to atomic charges. Tetrahedron 36:3219-3228.
13. Hasenhuetl PS, Schicker K, Koenig X, Li Y, Sarker S, Stockner T, Sucic S, Sitte HH, Freissmuth M, and Sandtner W (2015) Ligand selectivity among the dopamine and serotonin transporters specified by the forward binding reaction. Mol Pharmacol 88:12-18.
14. Henry LK, Iwamoto H, Field JR, Kaufmann K, Dawson ES, Jacobs MT, Adams C, Felts B, Zdravkovic I, and Armstrong V et al. (2011) A conserved asparagine residue in transmembrane segment 1 (TM1) of serotonin transporter dictates chloridecoupled neurotransmitter transport. J Biol Chem 286:30823-30836.
15. Hess B, Kutzner C, van der Spoel D, and Lindahl E (2008) GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4:435-447.
16. HilberB, Scholze P, DorostkarMM, SandtnerW, HolyM, BoehmS, SingerEA, and Sitte HH (2005) Serotonin-Transporter mediated efflux: A pharmacological analysis of amphetamines and non-Amphetamines. Neuropharmacology 49:811-819.
17. Hofmaier T, Luf A, Seddik A, Stockner T, Holy M, Freissmuth M, Ecker GF, Schmid R, Sitte HH, and Kudlacek O (2014) Aminorex, a metabolite of the cocaine adulterant levamisole, exerts amphetamine like actions at monoamine transporters. Neurochem Int 73:32-41.
18. Hunter JD (2007) Matplotlib: A 2D graphics environment. Comput Sci Eng 9:90-95.
19. Iversen L (2000) Neurotransmitter transporters: fruitful targets for CNS drug discovery. Mol Psychiatry 5:357-362.
20. Jacobs MT, Zhang YW, Campbell SD, and Rudnick G (2007) Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasmfacing state of the transporter. J Biol Chem 282:29441-29447.
21. Jones G, Willett P, Glen RC, Leach AR, and Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727-748.
22. Just H, Sitte HH, Schmid JA, Freissmuth M, and Kudlacek O (2004) Identification of an additional interaction domain in transmembrane domains 11 and 12 that supports oligomer formation in the human serotonin transporter. J Biol Chem279:6650-6657.
23. Kaminski GA, Friesner RA, Tirado-Rives J, and Jorgensen WL (2001) Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 105: 6474-6487.
24. Korb O, Stötzle T, and Exner TE (2009) Empirical scoring functions for advanced protein-ligand docking with PLANTS. J Chem Inf Model 49:84-96.
25. Krishnamurthy H and Gouaux E (2012) X-ray structures of LeuT in substrate-free outward-open and apo inward-open states. Nature 481:469-474.
26. Kristensen AS, Andersen J, Jørgensen TN, Sørensen L, Eriksen J, Loland CJ, Strømgaard K, and Gether U (2011) SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev 63:585-640.
27. Mager S, Min C, Henry DJ, Chavkin C, Hoffman BJ, Davidson N, and Lester HA (1994) Conducting states of a mammalian serotonin transporter. Neuron 12: 845-859.
28. Mitchell SM, Lee E, Garcia ML, and Stephan MM (2004) Structure and function of extracellular loop 4 of the serotonin transporter as revealed by cysteine-scanning mutagenesis. J Biol Chem 279:24089-24099.
29. Penmatsa A, Wang KH, and Gouaux E (2013) X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature 503:85-90.
30. Penmatsa A, Wang KH, and Gouaux E (2015) X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine. Nat Struct Mol Biol 22:506-508.
31. Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, Partilla JS, Rothman RB, and Katz JL (2015) Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend 147: 1-19.
32. Rickli A, Hoener MC, and Liechti ME (2015a) Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol 25:365-376.
33. Rickli A, Kopf S, Hoener MC, and Liechti ME (2015b) Pharmacological profile of novel psychoactive benzofurans. Br J Pharmacol 172:3412-3425.
34. Rothman RB and Baumann MH (2003) Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479:23-40.
35. Rothman RB, Partilla JS, Baumann MH, Lightfoot-Siordia C, and Blough BE (2012) Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters. J Pharmacol Exp Ther 341: 251-262.
36. Saha K, Partilla JS, Lehner KR, Seddik A, Stockner T, Holy M, Sandtner W, Ecker GF, Sitte HH, and Baumann MH (2015) 'Second-generation' mephedrone analogs, 4-MEC and 4-MePPP, differentially affect monoamine transporter function. Neuropsychopharmacology 40:1321-1331.
37. Sali A and Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779-815.
38. Sandtner W, Schmid D, Schicker K, Gerstbrein K, Koenig X, Mayer FP, Boehm S, Freissmuth M, and Sitte HH (2014) A quantitative model of amphetamine action on the 5-HT transporter. Br J Pharmacol 171:1007-1018.
39. Schicker K, Uzelac Z, Gesmonde J, Bulling S, Stockner T, Freissmuth M, Boehm S, Rudnick G, Sitte HH, and Sandtner W (2012) Unifying concept of serotonin transporter-Associated currents. J Biol Chem 287:438-445.
40. Scholze P, Sitte HH, and Singer EA (2001) Substantial loss of substrate by diffusion during uptake in HEK-293 cells expressing neurotransmitter transporters. Neurosci Lett 309:173-176.
41. Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, and Sitte HH (2000) Transportermediated release: A superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther 293:870-878.
42. Seddik A, Holy M, Weissensteiner R, Zdrazil B, Sitte HH, and Ecker GF (2013) Probing the selectivity of monoamine transporter substrates by means of molecular modeling. Mol Inform 32:409-413.
43. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, and Liechti ME (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458-470.
44. Singh SK, Yamashita A, and Gouaux E (2007) Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature 448:952-956.
45. Sitte HH and Freissmuth M (2015) Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci 36:41-50.
46. Steinkellner T, Freissmuth M, Sitte HH, and Montgomery T (2011) The ugly side of amphetamines: short-And long-Term toxicity of 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-Amphetamine. Biol Chem 392:103-115.
47. Stockner T, Jurik A, Freissmuth M, Ecker GF, and Sitte HH (2014) Development of refined homology models: Adding the missing information to the medically relevant neurotransmitter transporters, in Membrane Transport Mechanism (Ziegler C and Krämer R, eds) pp 99-120, Springer, Berlin.
48. Stockner T, Montgomery TR, Kudlacek O, Weissensteiner R, Ecker GF, Freissmuth M, and Sitte HH (2013) Mutational analysis of the high-Affinity zinc binding site validates a refined human dopamine transporter homology model. PLOS Comput Biol 9:e1002909.
49. Sucic S, Dallinger S, Zdrazil B, Weissensteiner R, Jørgensen TN, Holy M, Kudlacek O, Seidel S, Cha JH, and Gether U et al. (2010) The N terminus of monoamine transporters is a lever required for the action of amphetamines. J Biol Chem 285: 10924-10938.
50. Thévenaz P, Ruttimann UE, and Unser M (1998) A pyramid approach to subpixel registration based on intensity. IEEE Trans Image Process 7:27-41.
51. Wang KH, Penmatsa A, and Gouaux E (2015) Neurotransmitter and psychostimulant recognition by the dopamine transporter. Nature 521:322-327.
52. Yamashita A, Singh SK, Kawate T, Jin Y, and Gouaux E (2005) Crystal structure of a bacterial homologue of Na1/Cl-dependent neurotransmitter transporters. Nature 437:215-223.
53. Zhang YW and Rudnick G (2006) The cytoplasmic substrate permeation pathway of serotonin transporter. J Biol Chem 281:36213-36220.